Several other equities research analysts have also commented on the company. Peel Hunt restated a hold rating on shares of Genus in a research note on Thursday, December 6th. Liberum Capital upgraded Genus to a buy rating and upped their price target for the stock from GBX 2,400 ($31.36) to GBX 2,500 ($32.67) in a research note on Tuesday, March 5th. Finally, Kepler Capital Markets upgraded Genus to a buy rating and increased their target price for the company from GBX 2,475 ($32.34) to GBX 2,630 ($34.37) in a research note on Thursday, December 6th.
Shares of LON:GNS opened at GBX 2,390 ($31.23) on Monday. The stock has a market cap of $1.58 billion and a price-to-earnings ratio of -221.30. The company has a quick ratio of 1.32, a current ratio of 2.08 and a debt-to-equity ratio of 22.58. Genus has a 12 month low of GBX 2,090 ($27.31) and a 12 month high of GBX 2,998 ($39.17).
Genus Company Profile
Genus plc operates as an animal genetics company in North America, Latin America, rest of Europe, the Middle East, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand.
Further Reading: Return On Assets
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.